Blood cancers

Dasatinib discontinuation after 1 Year possible in some CML patients

Second-line dasatinib can be discontinued in patients with chronic myeloid leukaemia after they have sustained deep molecular response for more than 1 year, a study suggests. Writing in the Lancet Haematology the researchers said most haematologists think that patients should have achieved sustained deep molecular response for at least 2 years before imatinib treatment is ...

Already a member?

Login to keep reading.

© 2021 the limbic